Abstract
Background: The patients with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory distress syndrome (ARDS) may require prolonged mechanical ventilation which often results in lung fibrosis, thus worsening the prognosis and increasing fatality rates. A mesenchymal stromal cell (MSC) therapy may decrease lung inflammation and accelerate recovery in COVID-19. In this context, some studies have reported the effects of MSC therapy for patients not requiring invasive ventilation or during the first hours of tracheal intubation. However, this is the first case report presenting the reduction of not only lung inflammation but also lung fibrosis in a critically ill long-term mechanically ventilated patient with COVID-19.
Case Presentation: This is a case report of a 30-year-old male patient with COVID-19 under invasive mechanical ventilation for 14 days in the intensive care unit (ICU), who presented progressive clinical deterioration associated with lung fibrosis. The symptoms onset was 35 days before MSC therapy. The patient was treated with allogenic human umbilical-cord derived MSCs [5 × 107 (2 doses 2 days interval)]. No serious adverse events were observed during and after MSC administration. After MSC therapy, PaO2/FiO2 ratio increased, the need for vasoactive drugs reduced, chest CT scan imaging, which initially showed signs of bilateral and peripheral ground-glass, as well as consolidation and fibrosis, improved, and the systemic mediators associated with inflammation decreased. Modulation of the different cell populations in peripheral blood was also observed, such as a reduction in inflammatory monocytes and an increase in the frequency of patrolling monocytes, CD4+ lymphocytes, and type 2 classical dendritic cells (cDC2). The patient was discharged 13 days after the cell therapy.
Conclusions: Mesenchymal stromal cell therapy may be a promising option in critically ill patients with COVID-19 presenting both severe lung inflammation and fibrosis. Further clinical trials could better assess the efficacy of MSC therapy in critically ill patients with COVID-19 with lung fibrosis associated with long-term mechanical ventilation.
Background
SARS-CoV-2 infections present different clinical presentations (). Severe pneumonia and acute respiratory failure may occur, often requiring long-term hospitalization in the intensive care units (ICUs) and prolonged ventilatory assistance (). Patients with severe/critical coronavirus disease 2019 (COVID-19) usually present a hyperinflammatory and hypercoagulable state, which may also compromise multiple organs (). The prognosis of patients with COVID-19 has been associated with age, comorbidities, and duration of mechanical ventilation (, ). The latter may result in lung fibrosis, thus, impairing gas exchange and increasing the fatality rates.
To date, few pharmacological measures, such as dexamethasone, have been shown to decrease mortality in mechanically ventilated patients with COVID-19 (, ); however, this has not been observed in the critically ill patients with COVID-19 with lung fibrosis associated with long-term mechanical ventilation. Despite significant therapeutic advances with increased knowledge and definition of standard protocols, critical COVID-19 remains a life-threatening disease and novel therapeutic strategies are urgently needed.
The mesenchymal stromal cells (MSCs) have been evaluated in compassionate use or clinical trials to treat COVID-19 pneumonia (–). The rationale of this therapy is to direct the immunomodulatory properties of the MSCs to control the hyperinflammatory state and improve respiratory function (). Most of the protocols, however, included patients with the early-stage disease or shortly after tracheal intubation. Little attention, however, has been given to late-stage critical cases of acute respiratory distress syndrome (ARDS) associated with COVID-19, in which extensive lung damage and fibrosis have already occurred, thus worsening the prognosis and increasing the fatality rates.
In this study, we report a case of a 30-year-old critically ill long-term mechanically ventilated patient with COVID-19 with severe lung inflammation and fibrosis treated with umbilical cord-derived MSCs (UC-MSCs).
Case Presentation
A 30-year-old male patient with no known comorbidities presented on Jun 6 with myalgia, headache, shortness of breath with moderate efforts at illness day 3, SpO2 > 95%, and a positive test for SARS-CoV-2 by nasopharyngeal reverse transcription (RT)-PCR. At this point, the CT scan showed parenchymal ground-glass opacities in up to 25% of the lung parenchyma. The patient was medicated and discharged, returning at illness day 6 with worsened dyspnea, SpO2 = 88% at ambient air, >50% altered lung parenchyma on CT, being classified as severe (). He was admitted to the ICU at São Rafael Hospital, Salvador, Brazil, receiving oxygen therapy, bronchodilators, anticoagulant, methylprednisolone (120 mg/day), and antibiotics (ceftriaxone + azithromycin). The patient was treated with high-flow nasal oxygen, a non-rebreathing mask, and required pronation to sustain SpO2, but did not respond, progressing with desaturation, respiratory acidosis, and septic shock, requiring orotracheal intubation on illness day 15, being clinically diagnosed with critical COVID-19. Laboratory testing was consistent with cytokine storm, with reduced lymphocyte counts, increased C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), fibrinogen, and ferritin, along with PaO2/FiO2 < 200. The patient required vasoactive drugs to keep mean arterial pressure above 65 mmHg. On the following days, serial SARS-CoV-2 reverse transcription PCR (RT-PCR) results were persistently positive, and secondary infections with Stenotrophomonas and Klebsiella pneumoniae were detected in the tracheal aspirate, treated with antibiotics. Tracheostomy was performed on Jun 29. The patient presented clinical deterioration on illness day 30 and CT imaging demonstrated radiological worsening with an ARDS pattern, lesions affecting >75% of the lung parenchyma, and foci of interstitial fibrosis. A cell therapy protocol with UC-MSCs was then applied on a compassionate use basis, following informed consent given by the family of the patient.
Mesenchymal stromal cells were obtained from the umbilical cord tissue at a cGMP facility at the Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil and cryopreserved at passage 3 in 50 ml of a cryopreservation solution containing Plasmalyte, 3% human albumin, and 5% dimethyl sulfoxide (DMSO) and stored in cryobags at <-135°C. The identity of MSC was assessed by flow cytometry (Stemflow Human MSC Analysis kit, BD Biosciences, NJ, USA) and in vitro trilineage differentiation assays (StemPro Osteogenesis and Adipogenesis kits, Thermo Fisher Scientific, MA, USA) (Supplementary Figures 1A–E). Genetic stability was evaluated by G-band karyotype, as previously described () (Supplementary Figure 1F). Sterility was evaluated by culture for anaerobic, aerobic bacteria and fungi, endotoxin levels, and mycoplasma test. The potency was evaluated by measuring IDO1 mRNA expression by quantitative reverse transcription PCR (RT-qPCR) after stimulation with IFNγ (Supplementary Figure 2A), as described previously (). Finally, the product hemocompatibility was tested by evaluating tissue factor (CD142) expression by flow cytometry and by performing thromboelastography (TEG) studies in the citrate blood samples obtained from three different donors, as previously described (Supplementary Figures 2B–D) (). Finally, the cell viability was checked before cryopreservation, 48 h after, and at the time of infusion, by flow cytometry with 7AAD (BD Biosciences) (Supplementary Figure 2E).
Approximately 30–60 min before the infusions, the patient received 50 mg diphenhydramine to prevent the infusion-related allergy. The cells were thawed in a 37°C water bath and immediately taken to the patient bedside for intravenous infusion, via gravity, over 30–40 min. The patient was followed up by daily clinical evaluations and laboratory testing. The radiological evaluation was performed by serial chest X-rays and CT scans. Additionally, the blood samples were collected on day 1 (pre-infusion), day 3, and day 7 following treatment initiation with MSCs for the evaluation of cytokines and chemokines by Luminex and immune cell populations by flow cytometry (days 1, 3, 7, and 14 following treatment initiation; antibody information in Supplementary Table 1; gating strategy in Supplementary Figures 3, 4). To evaluate the overall profile of biomarkers, an unsupervised hierarchical cluster with the Luminex and flow cytometry assay values was performed using Ward's method. In this analysis, the dendrograms represent the Euclidean distance (inferring degree of similarity). The values were normalized using the Z-score method. To calculate a fold-change, day 1 was used as a reference.
Umbilical cord-derived-mesenchymal stromal cells are characterized according to their ability to adhere to plastic, and high expression (>95%) of CD90, CD105, CD44, and CD73, and low expression (<2%) of CD45, CD34, and CD117 (Supplementary Figure 1E), and also by their in vitro adipogenic, osteogenic, and chondrogenic differentiation, with a normal karyotype (Supplementary Figure 1F) ().
Two intravenous administrations of UC-MSCs (50 million cells/infusion) were performed at illness days 30 and 32. The infusions were well-tolerated, and no adverse events were observed. The patient showed a rapid improvement in oxygenation, requiring progressively lower levels of vasopressors until hemodynamic stability without vasopressors was achieved 9 days post the UC-MSC infusion. The patient was discharged 13 days after UC-MSC infusion. The variations in PaO2/FiO2, Sequential Organ Failure Assessment (SOFA) score, lymphocyte counts, CRP, ferritin, and D-dimer, along with the dynamic changes seen in chest CT are shown (Figure 1). The control CT scan showed significant absorption of bilateral pulmonary infiltrates, maintaining only retractable opacities.
Figure 1
To evaluate the possible mechanisms of action of MSCs in the immune cells and soluble mediators, we performed the Luminex and flow cytometry analyses follow cell therapy initiation. An unsupervised hierarchical analysis was performed with Luminex data, and three clusters of plasma biomarkers were established. On the first and second clusters, a slight increase in the plasma cytokine levels was observed on day 3, compared with day 1. On day 7, the levels of most cytokines approached the first measured value (Figures 2A,B). On the third cluster, the increase was more accentuated and was maintained at day 7 (Figure 2A). For each cluster, we performed enrichment analysis on the NCI Nature database. The first was enriched mainly to the regulation of transcription and signaling process in the lymphocytes. The second was enriched with IL-27, calcium, and IL-23 signaling. While the third was enriched to IL-12 signaling events (Figure 2B). The biomarkers that showed the greatest discrepancies (±0.4-fold change) at day 3 were IL-2RA, IL-18, IL-6, and M-CSF (Figure 2C).
Figure 2
The flow cytometry analysis demonstrated that up to 7 days following treatment initiation, classical monocytes (CD14++CD16−) were enriched in the peripheral blood, whereas on day 14, the patrolling monocytes (CD14+CD16++) were the most prevailing monocyte subpopulation (Figure 3A). The substantial alterations of chemokine receptors expression over time post-treatment, with an increase on CCR5+ receptors and decrease of CCR7+ (Figure 3B). Additionally, the degree of monocyte activation was substantially altered following the treatment in the inflammatory monocyte subpopulation, where it is possible to observe a decrease in these activated monocytes on day 3 and day 7, with a subsequent increase on day 14, where the profile is similar to the baseline (Figure 3C). Regarding monocyte polyfunctionality in response to a toll-like receptor-4 (TLR-4) agonist [lipopolysaccharide (LPS), 1 μg/ml], there was a peak of multiple cytokine producer monocytes on day 3, suggesting higher polyfunctional activity in this period (Figures 3D–F).
Figure 3
The frequencies of CD4+ and CD8+ T cells in peripheral blood presented similar changes over time following the MSC treatment initiation. In both cases, there was observed a slight increase at day 3, with progressive reduction at day 7 and day 14 (Figure 4A). The evaluation of differential chemokine receptor expression of CCR6 and CXCR3 on circulating CD4+ lymphocytes revealed higher frequencies of CXCR3−CCR6− (Th2) subpopulation following treatment (Figure 4B). In activated cells, the profile changes and CXCR3+CCR6− are more frequent (Figure 4C). Interestingly, the patient exhibited a reduction in naïve CD4+ T-cells frequencies over time along with the increased frequencies of terminally differentiated CD4+ T cells (Figure 4D). The activated TCD4+ cells were more terminally differentiated and effector on the first day, comparing with the other days (Figure 4E). Of note, the conventional dendritic cells 2 (cDC2) frequency peaked on day 3 after treatment, returning to the basal levels afterward (Figure 4F).
Figure 4
Discussion and Conclusions
The MSC-based therapy protocols to treat COVID-19 have been directed mainly to patients with moderate and severe clinical presentations (–). Few studies included critically ill patients with COVID-19 under invasive mechanical ventilation (–). Although preliminary, the published data suggest that the critically ill patients who presented benefits with the MSC treatment were successfully extubated after receiving MSCs shortly following intubation (). The results of the first published randomized controlled trials also support enhanced time to recovery and improved survival following the treatment with MSCs in the patients with COVID-19 ARDS of different severity levels, supporting the trends for improved radiological recovery (, ). In this study, we report the case of a patient successfully treated with MSCs 14 days after tracheal intubation and invasive mechanical ventilation, in which time association between MSC infusion and amelioration of clinical, oxygenation, and laboratory parameters were observed. Importantly, intravenous administration of UC-MSCs was not associated with serious adverse events. This is particularly important in the context of severe/critical COVID-19, due to a thromboinflammatory state ().
The initial anti-SARS-CoV-2 response starts with the activation of innate immune cells, which function as antigen presenters and produce type I interferons (). As the infection progresses and tissue injury increases, an exacerbated inflammatory response, with the high levels of pro-inflammatory mediators is seen (). Prolonged exposure to a cytokine storm scenario as an expression of the dysregulated immune response, leads to macrophage activation syndrome, induced by interleukin-1β (IL1β) (), defects in the antigen presentation induced by IL-6, decreased HLA-DR expression in monocytes, CD4+T cell depletion, the rapid spread of the virus, and secondary organ dysfunction (). Poor innate immune response in severe COVID-19 was recently characterized as immune paralysis, resembling some characteristics of bacterial sepsis (). Our results demonstrate that, after MSC therapy, the monocytes increased HLA-DR expression and showed an increased ability to respond to TLR4 ligand stimulation. In addition, we observed a marked increase in the frequency of cDC2, accompanied by a transient increase in the serum levels of different cytokines that are involved in antigen presentation, antiviral response, and differentiation of effector CD4+ T cells (). Interestingly, one of the upregulated pathways found was IL-27 signaling, and dendritic cell-derived IL-27 has been associated with the induction of Treg in lung parenchyma and resolution of immunopathology upon infection with respiratory viruses ().
After day 3, we observed a reduction in proinflammatory cytokines, and the subset of naïve CD4+ T cells, along with the increased frequencies of the terminally differentiated subset with Th2 markers. Finally, after day 7, we observed an increased frequency of patrolling monocytes, a population involved in the resolution of inflammation and healing (), which migrates to the lungs, differentiate into CD11c+, resident lung macrophage, and act in a specialized way as effector cells (). In addition, the patrolling monocytes respond strongly to viruses via the TLR7/8-MEK pathway, producing cytokines, such as TNFα and IL1β, as well as CCL5 and CXCL10 chemokines (, ).
In summary, the results of this case report support a potential role for MSC-based therapies not only in the early stages of COVID-19, as has been extensively explored, but also in the advanced stages of critical disease facing clinical deterioration. Administration of UC-MSCs at day 30 of illness, and 14 days after orotracheal intubation, was still safe and associated with a significant change in the clinical course. Further clinical studies with proper design and sample size are required to confirm the efficacy of MSC-based therapies in the advanced stages of severe/critical COVID-19.
Funding
This study was supported by grants from the Serrapilheira Foundation, D'Or Institute for Research and Education (IDOR), CNPq, and CAPES.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of CEP Hospital São Rafael. The patients/participants provided their written informed consent to participate in this study. Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient or the parent/guardian/relative of the patient.
Author contributions
BS and PR: conception and design, provision of study material, data analysis and interpretation, manuscript writing, financial support, and final approval of the manuscript. AG and RP: performed the cell infusions, clinical evaluation, data collection, and analysis. GM and PP: data collection and analysis. KS, BP, LF, and CN: cell manufacturing, characterization, and product quality control. FC and HC-F-N: luminex experiments and cytokine analysis. BA, BB-D, MA-P, and RT: flow cytometry evaluation, data analysis, and interpretation. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors thank Ms. Alice Andrade for her technical support in sample processing and handling. We also thank the healthcare team at the ICU of São Rafael Hospital for the support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.767291/full#supplementary-material
Supplementary Figure 1Characterization of UC-MSCs. Phase contrast microscopy imaging of UC-MSCs cultured with growth media (A), or exposed to (B) adipogenic, (C) osteogenic or (D) chondrogenic differentiation media. Differentiation was confirmed by Oil red (B), Alizarin red (C) or Alcian Blue (D) staining. (E) Immunophenotype evaluated by flow cytometry analysis for MSC markers CD90, CD44, CD105 and CD73 and a cocktail of negative markers (CD45, CD34 and CD117). Light histograms represent staining with isotype controls. (D) G-band karyotype representative image of normal (46, XX) karyotype.
Supplementary Figure 2Evaluation of potency, hemocompatibility and cell viability. (A) MSCs were evaluated for IFN-γ-induced IDO1 mRNA expression. (B) Tissue factor (CD142) expression was evaluated by flow cytometry. Light histogram represents staining with isotype control. (C,D) Results of thromboelastography analysis using blood/MSC mixture. The analysis was performed with blood donated from three independent healthy donors. Data are represented as mean SD. INTEM: contact-activated assay to evaluate clot formation via the intrinsic pathway; EXTEM: a tissue-factor activated assay to evaluate clot formation via the Extrinsic pathway. CT: clotting time; CFT: clot formation time; MCF: maximum clot firmness; *P < 0.05. (E) Results of cell viability analysis performed before cryopreservation, 48 h after cryopreservation and at the moment of cell infusion, evaluated by 7AAD flow cytometry assay.
Supplementary Figure 3Gating strategy displaying the analysis of human monocytes. Peripheral Blood mononuclear cells (PBMCs) were stained using the panel indicated in the method section for quantitative analysis of chemokine receptor expression in monocytes. Samples were gated on monocytes based on SSC-A (complexity) and FSC-A (size) (A), single events (B) HLA-DR+ and DUMP - cells (C), monocyte subtype based on CD14 and CD16 expression (D), CX1CR3 (E), CCR2 (F), CCR7 (G), CCR6 (H), and CCR5 (I) expression.
Supplementary Figure 4Gating strategy display the analysis of T lymphocytes in regard to memory phenotype and function. Peripheral Blood mononuclear cells (PBMCs) were stained using the panel indicated in the method section for quantitative analysis of memory and function markers in both CD4+ and CD8+ T cells. Samples were gated on monocytes based on SSC-A (complexity) and FSC-A (size) (A), single events (B), CD3+CD45+ cells (T lymphocytes) (C), CD4 and CD8 T cells (D), CXCR3 and CCR6 (T helper subtype) (E), and CD45 and CD27 (memory markers) (F).
Supplementary Table 1List of antibodies used for the flow cytometry analyses.
- RT-PCR
reverse transcription PCR
- cGMP
current good manufacturing practices.
Abbreviations
References
1.
AzoulayEZafraniLMirouseALenglinéEDarmonMChevretS. Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Med. (2020) 46:1651–2. 10.1007/s00134-020-06120-4
2.
VelavanTPMeyerCG. The COVID-19 epidemic. Trop Med Int Health. (2020) 25:278–80. 10.1111/tmi.13383
3.
RobbaCBattagliniDBallLPatronitiNLoconteMBrunettiIet al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol. (2020) 279:103455. 10.1016/j.resp.2020.103455
4.
ZhouFYuTDuRFanGLiuYLiuZet al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/S0140-6736(20)30566-3
5.
ArmstrongRAKaneADCookTM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia. (2020) 75:1340–9. 10.1111/anae.15201
6.
Recovery Collaborative GroupHorbyPLimWSEmbersonJRMafhamMBellJLet al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. (2020) 384:693–704. 10.1056/NEJMoa2021436
7.
CacciapagliaGCotCSanninoF. Second wave COVID-19 pandemics in Europe: a temporal playbook. Sci Rep. (2020) 10:15514. 10.1038/s41598-020-72611-5
8.
LengZZhuRHouWFengYYangYHanQet al. Transplantation of ACE2− mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. (2020) 11:216–28. 10.14336/AD.2020.0228
9.
TangLJiangYZhuMChenLZhouXZhouCet al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. (2020) 14:664–73. 10.1007/s11684-020-0810-9
10.
ShuLNiuCLiRHuangTWangYHuangMet al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. (2020) 11:361. 10.1186/s13287-020-01875-5
11.
MengFXuRWangSXuZZhangCLiY. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. (2020) 5:172. 10.1038/s41392-020-00286-5
12.
MazzeoASantosEJC. Mesenchymal stem cells in the treatment of coronavirus-induced pneumonia (COVID-19). Einstein. (2020) 18:eCE5802. 10.31744/einstein_journal/2020CE5802
13.
PengHGongTHuangXSunXLuoHWangWet al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res Ther. (2020) 11:291. 10.1186/s13287-020-01802-8
14.
LiangBChenJLiTWuHYangWLiYet al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine. (2020) 99:e2142910.1097/MD.0000000000021429
15.
ZhangYDingJRenSWangWYangYLiSet al. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. (2020) 11:207. 10.1186/s13287-020-01725-4
16.
ChenXShanYWenYSunJDuH. Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects. J Infect. (2020) 81:647–79. 10.1016/j.jinf.2020.05.020
17.
ZhuYZhuRLiuKLiXChenDBaiDet al. Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: a case report. Infect Drug Resist. (2020) 13:3295–300. 10.2147/IDR.S272645
18.
DilogoIHAditianingsihDSugiartoAet al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. (2021) 10:1279–87. 10.1002/sctm.21-0046
19.
ShiLWangLXuRZhangCXieYLiuKet al. Mesenchymal stem cell therapy for severe COVID-19. Sig Transduct Target Ther. (2021) 6:58. 10.1038/s41392-021-00754-6
20.
da SilvaKNGobattoALNCosta-FerroZSMCavalcanteBRRCariaACIdeAragão França LSet al. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?Stem Cell Res Ther. (2021) 12:425. 10.1186/s13287-021-02502-7
21.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available online at: https://www.covid19treatmentguidelines.nih.gov/ (accessed November 23, 2020).
22.
MendonçaMVLaroccaTFde Freitas SouzaBSVillarrealCFSilvaLFMatosACet al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther. (2014) 5:126. 10.1186/scrt516
23.
Rovira GonzalezYILynchPJThompsonEEStultzBGHurshDA. In vitro cytokine licensing induces persistent permissive chromatin at the indoleamine 2,3-dioxygenase promoter. Cytotherapy. (2016) 18:1114–28. 10.1016/j.jcyt.2016.05.017
24.
MollGAnkrumJAKamhieh-MilzJBiebackKRingdénOVolkHDet al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. (2019) 25:149–63. 10.1016/j.molmed.2018.12.006
25.
DominiciMLe BlancKMuellerISlaper-CortenbachIMariniFKrauseDet al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy. (2006) 8:315–7. 10.1080/14653240600855905
26.
Sánchez-GuijoFGarcía-ArranzMLópez-ParraMMonederoPMata-MartínezCSantosAet al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. (2020) 25:100454. 10.1016/j.eclinm.2020.100454
27.
GuoZChenYLuoXHeXZhangYWangJ. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care. (2020) 24:420. 10.1186/s13054-020-03142-8
28.
SenguptaVSenguptaSLazoAWoodsPNolanABremerN. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. (2020) 29:747–754. 10.1089/scd.2020.0080
29.
ShiLHuangHLuXYanXJiangXXuRet al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Sig Transduct Target Ther. (2021) 6:58. 10.1038/s41392-021-00488-5
30.
LanzoniGLinetskyECorreaD. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. (2021) 10:660–73. 10.1002/sctm.20-0472
31.
GuSXTyagiTJainKGuVWLeeSHHwaJMet al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. (2020) 18:194–209. 10.1038/s41569-020-00469-1
32.
HadjadjJYatimNBarnabeiLCorneauABoussierJSmithNet al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. (2020) 369:718–24. 10.1126/science.abc6027
33.
HuangCWangYLiXRenLZhaoJHuYet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
34.
KyriazopoulouELeventogiannisKNorrby-TeglundADimopoulosGPantaziAOrfanosSEet al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. (2017) 15:172. 10.1186/s12916-017-0930-5
35.
Giamarellos-BourboulisEJNeteaMGRovinaNAkinosoglouKAntoniadouAAntonakosNet al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. (2020) 27:992–1000.e3. 10.1016/j.chom.2020.04.009
36.
van der PollTvan de VeerdonkFLSciclunaBPNeteaMG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. (2017) 17:407–20. 10.1038/nri.2017.36
37.
ShinJYWangCYLinCCChuCL. A recently described type 2 conventional dendritic cell (cDC2) subset mediates inflammation. Cell Mol Immunol. (2020) 17:1215–7. 10.1038/s41423-020-0511-y
38.
PyleCJUwadiaeFISwiebodaDPHarkerJA. Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology. PLoS Pathog. (2017) 13:e1006640. 10.1371/journal.ppat.1006640
39.
AuffrayCFoggDGarfaMElainGJoin-LambertOKayalSet al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. (2007) 317:666–70. 10.1126/science.1142883
40.
JakubzickCTackeFGinhouxFWagersAJvan RooijenNMackMet al. Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. J Immunol. (2008) 180:3019–27. 10.4049/jimmunol.180.5.3019
41.
CrosJCagnardNWoollardKPateyNZhangSYSenechalBet al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. (2010) 33:375–86. 10.1016/j.immuni.2010.08.012
42.
CarlinLMStamatiadesEGAuffrayCHannaRNGloverLVizcay-BarrenaGet al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. (2013) 153:362–75. 10.1016/j.cell.2013.03.010
Summary
Keywords
COVID-19, ARDS, mesenchymal stromal cells (MSCs), cell therapy, immunomodulation, fibrosis
Citation
Silva KN, Pinheiro PCG, Gobatto ALN, Passos RH, Paredes BD, França LSA, Nonaka CKV, Barreto-Duarte B, Araújo-Pereira M, Tibúrcio R, Cruz FF, Martins GLS, Andrade BB, Castro-Faria-Neto HC, Rocco PRM and Souza BSF (2021) Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. Front. Med. 8:767291. doi: 10.3389/fmed.2021.767291
Received
30 August 2021
Accepted
05 October 2021
Published
17 November 2021
Volume
8 - 2021
Edited by
Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France
Reviewed by
Chao Zhang, Fifth Medical Center of the PLA General Hospital, China; Alireza Shafiei, Tehran University of Medical Sciences, Iran
Updates
Copyright
© 2021 Silva, Pinheiro, Gobatto, Passos, Paredes, França, Nonaka, Barreto-Duarte, Araújo-Pereira, Tibúrcio, Cruz, Martins, Andrade, Castro-Faria-Neto, Rocco and Souza.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bruno Solano de Freitas Souza bruno.solano@fiocruz.brPatricia Rieken Macêdo Rocco prmrocco@biof.ufrj.br
This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.